Significantly reduced genoprevalence of vaccine-type HPV-16/18 infections among vaccinated compared to non-vaccinated young women 5.5 years after a bivalent HPV-16/18 vaccine (Cervarix®) pilot project in Uganda

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Kumakech, Edward ^a,b   Berggren, Vanja ^c,d   Wabinga, Henry ^b   Lillsunde Larsson, Gabriella ^a,e   Helenius, Gisela ^a,e   Kaliff, Malin ^e   Karlsson, Mats ^a,e   Kirimunda, Samuel ^b   Musubika, Caroline ^b   Andersson, Sören ^a,e  

^a ÖREBRO UNIVERSITY   (Sweden)

^b MAKERERE UNIVERSITY   (Uganda)

^c LUND UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Örebro University   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ADOLESCENT; ADULT; ANALYTICAL EQUIPMENT; ARTICLE; ASSAY; BLOOD SAMPLING; BODY MASS; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; COMPARATIVE STUDY; CONCURRENT SEXUAL PARTNERSHIP; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFICACY; FEMALE; GENOTYPE; HIV RAPID TEST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MICROARRAY ANALYSIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PILOT STUDY; POLYMERASE CHAIN REACTION; PREDICTION; PREVALENCE; RISK FACTOR; SYPHILIS; TREPONEMA PALLIDUM HEMAGGLUTINATION TEST; UGANDA; URBAN AREA; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS STRAIN; YOUNG ADULT; DRUG EFFECTS; GENETICS; HIV INFECTIONS; IMMUNOLOGY; MASS IMMUNIZATION; MICROBIOLOGY; MIXED INFECTION; ORGANIZATION AND MANAGEMENT; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE;

ADOLESCENT; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HIV INFECTIONS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNIZATION PROGRAMS; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PILOT PROJECTS; PREVALENCE; SYPHILIS; UGANDA; YOUNG ADULT;

EID: 84982091440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160099     Document Type: Article

References (36)

1. International Agency for Research on Cancer (IARC) and WHO: Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at http://globocan.iarc.fr/pages/fact-sheet-population.
2. Wabinga HR, Nambooze S, Amulen PM, Okello C, Mbus L, Parkin DM. Trends in the incidence of cancer in Kampala, Uganda 1991-2010. Int J Cancer. 2014 Jul 15; 135(2):432-9. doi: 10.1002/ijc.28661 PMID: 24615279
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1): 12-9. PMID: 10451482
4. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24S3: S1-S10.
5. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6): 518-27. PMID: 12571259
6. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect. Agent Cancer 2009; 4: 8. doi: 10.1186/1750-9378-4-8 PMID: 19486508
7. International Agency for Research on Cancer (IARC). Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B: A Review of Human Carcinogens: Biological Agents. Lyon: International Agency for Research on Cancer 2012.
8. Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013; 445: 224-231. doi: 10.1016/j.virol.2013.07.015 PMID: 23928291
9. Bernard HU, Calleja-Macias IE, Dunn ST. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer. 2006; 118(5): 1071-6. PMID: 16331617
10. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70-79. doi: 10.1016/j.virol.2010.02.002 PMID: 20206957
11. Odida M, de Sanjosé S, Quint W, Bosch FX, Klaustermeier J, Weiderpass E. Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis 2008; 8: 85. doi: 10.1186/1471-2334-8-85 PMID: 18577214
12. Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbonye AK, Wabwire FM. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer 2011; 6: 11. doi: 10.1186/1750-9378-6-11 PMID: 21749691
13. Banura C, Franceschi S, Doorn LJ, Arslan A, Wabwire-Mangen F, Mbidde EK, et al. Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis 2008; 197(4): 555-62. doi: 10.1086/526792 PMID: 18237268
14. Odida M, Sandin S, Mirembe F, Kleter B, Quint W, Weiderpass E. HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study. Infectious Agents and Cancer 2011, 6:8 doi: http://www.infectagentscancer.com/content/6/1/8 PMID: 21702999
15. Banura C, Sandin S, van Doorn L, Quint W, Kleter B, Wabwire-Mangen F, Mbidde EK and Weiderpass E. Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda. Infectious Agents and Cancer 2010, 5:7. doi: 10.1186/1750-9378-5-7 PMID: 20380709
16. Banura C, Franceschi S, van Doorn LJ, Arslan A, Kleter B, Wabwire-Mangen F, Mbidde EK, Quint W, Weiderpass E. Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Int J Cancer. 2008; 123(9): 2180-7. doi: 10.1002/ijc.23762 PMID: 18711697
17. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low-and middle income countries. Bull World Health Organ 2011; 89: 821-830B. doi: 10.2471/BLT.11.089862 PMID: 22084528
18. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374(9686): 301-14. doi: 10.1016/S0140-6736(09)61248-4 PMID: 19586656
19. Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R, et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014 Sep 3; 32(39): 5087-97. doi: 10.1016/j.vaccine.2014.06.038 Epub 2014 Jul 10. PMID: 25018097
20. Palmroth J, Merikukka M, Paavonen J, Apter D, Eriksson T, Natunen K, et al. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int. J. Cancer 2013; 131: 2832-2838.
21. Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis. BMC Infectious Diseases 2011; 11: 13. doi: http://www.biomedcentral.com/1471-2334/11/13 PMID: 21226933
22. Delerél Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, et al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross sectional study via home-based self-sampling. BMC Infectious Diseases 2014; 14:87. doi: 10.1186/1471-2334-14-87 PMID: 24552260
23. Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV Bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014; 110(11): 2804-11. doi: 10.1038/bjc.2014.198 PMID: 24736582
24. Mesher D, Soldana K, Howell-Jonesa R, Panwarb K, Manyengab P, Jit M, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunization in England. Vaccine 2014; 32: 26-32.
25. Polit F. P., & Beck C. T. Nursing research: Generating and assessing evidence for nursing practice. 2008. Philadelphia, PA: Lippincott, Williams, & Wilkins.
26. Altman D. G. Practical statistics for medical research. 1991. London: Chapman & Hall.
27. World Health Organization. Physical status: the use and interpretation of anthropometry: Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995; 854: 1-452. PMID: 8594834
28. Downing RG, Otten RA, Marum E, Biryahwaho B, Alwano-Edyegu MG, Sempala SD, et al. Optimizing the delivery of HIV counseling and testing services: the Uganda experience using rapid HIV antibody test algorithms. J Acquir Immune Defic Syndr Hum Retrovirol 1998 Aug 1; 18(4): 384-8. PMID: 9704945
29. Johnson D, Hirschkorn D, Busch MP. Evaluation of four alternative methods for determination of absolute CD4+ lymphocyte counts. The National Heart, Lung and Blood Institute Retrovirus Epidemiology Donor Study. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 1995; 15: 522-530.
30. Luger A, Schmidt BL, Gschnait F. Recent progress in syphilis serology. Wien Klin Wochenschr 1983; 95(13): 4 40-3.
31. Jeronimo J, Bansil P, Lim J, Peck R, Paul P, Amador JJ, et al. A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer 2014 Mar; 24(3):576-85. doi: 10.1097/IGC.0000000000000084 PMID: 24557438
32. Moses E, Pedersen HN, Mitchell SM, Sekikubo M, Mwesigwa D, Singer J, et al. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial. Trop Med Int Health. 2015 Oct; 20(10):1355-67. doi: 10.1111/tmi.12549 Epub 2015 Jun 28. PMID: 26031572
33. Pista A, Verdasca N, Oliveira A. Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test. J Med Virol 2011; 83(2): 272-6. doi: 10.1002/jmv.21952 PMID: 21181922
34. Chranioti A, Spathis A, Aga E, Meristoudis C, Pappas A, Panayiotides I, et al. Comparison of two commercially available methods for HPV genotyping: CLART HPV2 and Linear Array HPV Genotyping tests. Anal Quant Cytopathol Histpathol 2012; 34(5): 257-63. PMID: 23301385
35. Hubbard RA. Human papillomavirus testing methods. Arch Pathol Lab Med 2003; 127(8): 940-5. PMID: 12873165
36. Banura C, Sandin S, van Doorn LJ, Quint W, Kleter B, Wabwire-Mangen F, et al. Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda. Infect Agent Cancer 2010; 5: 7. doi: 10.1186/1750-9378-5-7 PMID: 20380709